Amgen Share Price Target Lowered to $69.00 by UBS AG Analysts (AMGN)

Analysts at UBS AG (NYSE: UBS) lowered their price target on shares of Amgen (NASDAQ: AMGN) from $70.00 to $69.00 in a research report issued to clients and investors on Thursday. They currently have a “neutral” rating on the company’s shares.

Separately, analysts at Oppenheimer (NYSE: OPY) downgraded shares of Amgen from an “outperform” rating to a “perform” rating in a research note to investors on Thursday. Analysts at Zacks Investment Research upgraded shares of Amgen from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday. They now have a $83.00 price target on the stock. Also, analysts at Lazard Capital downgraded shares of Amgen from a “neutral” rating to a “sell” rating in a research note to investors on Monday, February 6th.

Amgen Inc. (Amgen) is an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products are Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body’s response to inflammatory diseases. In March 2011, the Company acquired BioVex Group, Inc.

Amgen opened at 67.36 on Thursday. Amgen has a 52-week low of $47.66 and a 52-week high of $70.00. The stock has a 50-day moving average of $67.05 and a 200-day moving average of $58.41. The company has a market cap of $53.619 billion and a price-to-earnings ratio of 16.54.

Stay ahead of the market with Analyst Ratings Network's daily email update that provides a summary of analysts' upgrades, downgrades and new coverage. Click here to register now.

Posted by Web Inquirer Staff on 11 Feb 2012. Filed under Markets. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.